Comparative Pharmacology
Head-to-head clinical analysis: LUSEDRA versus SANCTURA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUSEDRA versus SANCTURA.
LUSEDRA vs SANCTURA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Trospium chloride is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, thereby reducing detrusor muscle contractions and increasing bladder capacity.
5 mg orally once daily.
20 mg orally twice daily, with or without food. Maximum dose 20 mg twice daily.
None Documented
None Documented
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Terminal elimination half-life is approximately 12–20 hours in healthy adults, allowing twice-daily dosing.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Primarily renal (approximately 60% as unchanged drug and metabolites); biliary/fecal elimination accounts for ~30%.
Category C
Category C
Anticholinergic
Anticholinergic